ArticleThe World Allergy Organization journal2026
Autoallergy in chronic rhinosinusitis and its clinical relevance.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The presence of IgE autoantibodies against human proteins ("autoallergy") has been identified in different type 2 inflammation. Objective: The aim of this study was to evaluate the presence of autoallergy in chronic rhinosinusitis (CRS) and explore its clinical impact. Methods: Cross-sectional study with CRS patients and healthy controls. Three steps were followed: 1) IgE autoantibodies against Fatty Acid Binding Protein (FABP), FABP3 and FABP4, Eosinophil Peroxidase (EPX), and Eosinophil Cationic Protein (ECP) were measured. 2) The allergenic activity of these IgE autoantibodies was evaluated with basophil activation test (BAT) and skin prick test (SPT). 3) Association of these autoantibodies with some clinical outcomes was explored. Results: 22.3% in the CRS group and 12.1% in the control group had at least 1 IgE autoantibody (IgE-AA). In CRS and control group, the most frequent IgE-AA were against EPX (15.9% versus 5.4% Conclusion: IgE autoantibodies are presented in CRS patients and are associated with severe clinical outcomes. Accordingly, autoallergy could be an endophenotype in CRS with clinical relevance as a biomarker of disease activity. Further studies with larger cohorts are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.